LONDON (Alliance News) - On Thursday Hikma Pharmaceuticals PLC said its wholly-owned US subsidiary West-Ward Pharmaceuticals Corp has launched a new cancer drug in the US market.
West-Ward has launched Methotrexate for Injection in two different doses for the treatment of several types of cancer, alone or in combination with other chemotherapeutic drugs.
In addition they can be used in the treatment of psoriasis and rheumatoid arthritis.
According to human data research and information technology company IQVIA, US sales of these drugs amounted to approximately USD13 million in the 12 months ended March.
Chief Executive Officer of Hikma's Injectables division, Riad Mechlaoui, said this new launch will help "reduce the shortage of this product in the US market".
Hikma shares were trading 0.2% higher on Thursday at 1,237.50 pence each.
Hikma Pharmaceuticals (HIK)